Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030

Published:2018-10 Issue:4 Volume:69 Page:896-904
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Estes Chris,Anstee Quentin M.,Arias-Loste Maria Teresa,Bantel Heike,Bellentani Stefano,Caballeria Joan,Colombo Massimo,Craxi Antonio,Crespo Javier,Day Christopher P.,Eguchi Yuichiro,Geier Andreas,Kondili Loreta A.,Kroy Daniela C.,Lazarus Jeffrey V.,Loomba Rohit,Manns Michael P.,Marchesini Giulio,Nakajima Atsushi,Negro Francesco,Petta Salvatore,Ratziu Vlad,Romero-Gomez Manuel,Sanyal Arun,Schattenberg Jörn M.,Tacke Frank,Tanaka Junko,Trautwein Christian,Wei Lai,Zeuzem Stefan,Razavi Homie

Publisher

Elsevier BV

Subject

Hepatology

Reference69 articles.

1. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009;Younossi;Hepatology,2015

2. Population-based risk factors and resource utilization for HCC: US perspective;Sanyal;Curr Med Res Opin,2010

3. The global NAFLD epidemic;Loomba;Nat Rev Gastroenterol Hepatol,2013

4. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology;Chalasani;Gastroenterology,2012

5. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;Diabetologia,2016

Cited by 1326 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Immunosuppressive Regimens on Metabolic Dysfunction-associated Fatty Liver Disease Following Liver Transplantation;Journal of Clinical and Experimental Hepatology;2025-01

2. Therapeutic potential of palmitoleic acid in non-alcoholic fatty liver disease: Targeting ferroptosis and lipid metabolism disorders;International Immunopharmacology;2024-12

3. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

4. Metabolic dysfunction-associated steatotic liver disease and its link to cancer;Metabolism;2024-11

5. Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis;Molecular Metabolism;2024-11